OR WAIT null SECS
The partnership was sealed to support U.S. launch & commercialization of a medical device to help cancer patients manage and treat oral mucositis.
EVERSANA, a commercialization services provider for the life science industry, has announced a partnership with ChemoMouthpiece, LLC to support the launch and commercialization of its medical device, the Chemo Mouthpiece™.
The device is an intraoral ice pack that delivers cryotherapy to the oral cavity of a patient receiving chemotherapy, to manage and treat oral mucositis, a common and painful side effect of chemotherapy. The FDA recently granted Breakthrough Device Designation to the Chemo Mouthpiece™ for reducing the incidence and severity of oral mucositis caused by chemotherapy.
Under the partnership, EVERSANA will provide a full range of commercialization services to support the launch of the device in the US, including market access strategy, compliance and regulatory services, patient services, field deployment solutions, data and analytics, pricing strategy, and 3PL distribution services. The Chemo Mouthpiece™ is expected to launch in the US in late 2023.